Phase 2 Myelodysplastic Syndrome (MDS) Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Severe Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting
Phase 1Phase 2
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
Proton TherapyAcute Myeloid Leukemia (AML)Myelodysplastic Neoplasm+2 more
Institute of Hematology and Blood Transfusion, Czech Republic16 enrolled2 locationsNCT07532824
Recruiting
Phase 1Phase 2
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Myelodysplastic Syndrome (MDS)Severe Aplastic AnemiaHypo-Plastic MDS
National Heart, Lung, and Blood Institute (NHLBI)37 enrolled1 locationNCT03173937
Not Yet Recruiting
Phase 2
ALLG BM15: A Double-blind, Phase I/II, Randomised Study to Compare the Efficacy of Enzomenib Versus Placebo as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation in Subjects with Acute Myeloid Leukaemia (AML).
CancerMyelodysplastic Syndrome (MDS)
Australasian Leukaemia and Lymphoma Group53 enrolled2 locationsACTRN12626000019303
Recruiting
Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Fanconi AnemiaSevere Marrow FailureMyelodysplastic Syndrome (MDS)+1 more
Children's Hospital Medical Center, Cincinnati70 enrolled3 locationsNCT02143830
Not Yet Recruiting
Phase 2
MDS05/D2 - Phase Ib/II study for treatment of Myelodysplasia (MDS) with SRA515 and ASTX727,
Myelodysplastic Syndrome (MDS)Acute Myeloid Leukaemia (AML)
Australasian Leukaemia and Lymphoma Group (ALLG)86 enrolled1 locationACTRN12622001302741
Completed
Phase 2
Panobinostat with 5-azacytidine in patients with untreated high risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML).
Previously untreated high risk Myelodysplastic syndrome (MDS)Previously untreated Acute Myeloid Leukaemia (AML)
The Alfred Hospital40 enrolled1 locationACTRN12610000924055